ResMed Introduces AirFit P30i, Its First Top-of-Head-Connected Nasal Pillows CPAP Mask

ResMed (NYSE: RMD, ASX: RMD) today introduced its second top-of-head-connected CPAP mask for treating sleep apnea, a new nasal pillows option, AirFit P30i.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190411005140/en/

The mask’s “tube-up” connection, also featured on ResMed’s AirFit N30i nasal mask released in January, keeps tubing out of the wearer’s way so they can move and sleep in any position.

AirFit P30i fits 90 percent of wearers with just two frame sizes and three cushions, helping home medical equipment (HME) providers fit patients easier and faster.

“The AirFit P30i provides great freedom of movement for patients who want an unobtrusive nasal pillows mask,” said Jim Hollingshead, president of ResMed’s Sleep business. “This unique pillows tube-up frame is a great addition to our growing mask family, and it’s easy for sleep labs and HMEs to stock and fit.”

How AirFit P30i compares

In a clinical study comparing AirFit P30i to the other tube-up nasal pillows mask:

• CPAP users preferred AirFit P30i nearly 2 to 1.
• More than 70 percent whose preference was based on mask seal preferred AirFit P30i.
• Twice as many reported AirFit P30i is easier to use and more comfortable.

Availability

AirFit P30i is available today across Europe, Australia, and New Zealand. It will be available throughout the United States and Canada on Monday, April 15, and other countries later this year.

The mask joins ResMed’s portfolio of 30-plus CPAP masks, including its popular “tube-down” nasal pillows mask, AirFit P10, winner of the international Red Dot product design award.

“We believe that every patient is different, and we are committed to providing the best possible experience to everyone who needs CPAP therapy,” said Hollingshead. “That’s why ResMed offers a wide range of AirFit masks, and we’ll keep innovating to expand the portfolio.”

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries. To learn more, visit ResMed.com and follow @ResMed.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190411005140/en/

Contact information

For media:
Jayme Rubenstein
+1 858.836.6798
news@resmed.com

For investors:
Amy Wakeham
+1 858.836.5000
investorrelations@resmed.com